Bridgewater Associates LP Has $659,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Bridgewater Associates LP trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 65.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,515 shares of the biopharmaceutical company's stock after selling 21,706 shares during the period. Bridgewater Associates LP's holdings in Halozyme Therapeutics were worth $659,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in shares of Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 254 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at $33,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at $49,000. Toth Financial Advisory Corp acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at $57,000. Finally, FSC Wealth Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at $65,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $62.03, for a total value of $620,300.00. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at $10,778,084.68. This trade represents a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In the last 90 days, insiders have sold 60,000 shares of company stock valued at $3,425,000. Company insiders own 2.70% of the company's stock.

Wall Street Analyst Weigh In

HALO has been the topic of a number of analyst reports. Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Piper Sandler raised their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a "neutral" rating in a report on Monday, November 4th. HC Wainwright reissued a "buy" rating and set a $68.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, November 20th. Morgan Stanley raised their price target on Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an "overweight" rating in a report on Wednesday, August 7th. Finally, Benchmark reissued a "buy" rating and set a $60.00 price target on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $61.11.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded down $0.11 during trading hours on Tuesday, reaching $48.48. The stock had a trading volume of 1,177,145 shares, compared to its average volume of 1,369,173. The firm has a market capitalization of $6.17 billion, a PE ratio of 16.09, a price-to-earnings-growth ratio of 0.44 and a beta of 1.23. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The firm has a 50-day simple moving average of $53.08 and a 200-day simple moving average of $53.82. Halozyme Therapeutics, Inc. has a twelve month low of $33.15 and a twelve month high of $65.53.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.